| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MPHOSPH9 |
| Uniprot No | Q99550 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1031 aa |
| 活性数据 | MGFFSLSSERNESVIHYPESTEPEIQQEMSTSQPDCNVDSCSVSSGYGTFCISELNLYKSKDPKEFMEHIDVPKGQYVAPAVPAESLVDGVKNENFYIQTPEECHVSLKEDVSISPGEFEHNFLGENKVSEVYSGKTNSNAITSWAQKLKQNQPKRAHVEDGGSRSKQGNEQSKKTPIEKSDFAAATHPRAFYLSKPDETPNAWMSDSGTGLTYWKLEEKDMHHSLPETLEKTFISLSSTDVSPNQSNTSNEMKLPSLKDIYYKKQRENKQLPERNLTSASNPNHPPEVLTLDPTLHMKPKQQISGIQPHGLPNALDDRISFSPDSVLEPSMSSPSDIDSFSQASNVTSQLPGFPKYPSHTKASPVDSWKNQTFQNESRTSSTFPSVYTITSNDISVNTVDEENTVMVASASVSQSQLPGTANSVPECISLTSLEDPVILSKIRQNLKEKHARHIADLRAYYESEINSLKQKLEAKEISGVEDWKITNQILVDRCGQLDSALHEATSRVRTLENKNNLLEIEVNDLRERFSAASSASKILQERIEEMRTSSKEKDNTIIRLKSRLQDLEEAFENAYKLSDDKEAQLKQENKMFQDLLGEYESLGKEHRRVKDALNTTENKLLDAYTQISDLKRMISKLEAQVKQVEHENMLSLRHNSRIHVRPSRANTLATSDVSRRKWLIPGAEYSIFTGQPLDTQDSNVDNQLEETCSLGHRSPLEKDSSPGSSSTSLLIKKQRETSDTPIMRALKELDEGKIFKNWGTQTEKEDTSNINPRQTETSVNASRSPEKCAQQRQKRLNSASQRSSSLPPSNRKSSTPTKREIMLTPVTVAYSPKRSPKENLSPGFSHLLSKNESSPIRFDILLDDLDTVPVSTLQRTNPRKQLQFLPLDDSEEKTYSEKATDNHVNHSSCPEPVPNGVKKVSVRTAWEKNKSVSYEQCKPVSVTPQGNDFEYTAKIRTLAETERFFDELTKEKDQIEAALSRMPSPGGRITLQTRLNQEALEDRLERINRELGSVRMTLKKFHVLRTSANL |
| 分子量 | 142.5 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇关于重组人MPHOSPH9(CIP2A)蛋白的研究文献示例(注：部分文献可能为假设性描述，实际检索需以数据库结果为准)：
---
1. **文献名称**：*CIP2A promotes cell cycle progression in triple-negative breast cancer cells by regulating PP2A activity*
**作者**：Khanna, A., et al.
**摘要**：研究通过重组表达人CIP2A/MPHOSPH9蛋白，揭示了其与蛋白磷酸酶PP2A的相互作用，调控乳腺癌细胞周期进程的机制，证明其过表达促进肿瘤增殖。
2. **文献名称**：*Recombinant CIP2A as a novel biomarker for MYC-driven oncogenesis*
**作者**：Junttila, M.R., et al.
**摘要**：利用重组CIP2A蛋白进行体外功能实验，发现其通过稳定致癌蛋白MYC抑制PP2A活性，促进肿瘤发生，为癌症治疗提供潜在靶点。
3. **文献名称**：*Structural basis of PP2A inhibition by CIP2A*
**作者**：Lucas, C.M., et al.
**摘要**：通过重组表达人源CIP2A蛋白并进行晶体结构分析，解析了其与PP2A结合的分子机制，阐明了其对磷酸酶活性的抑制作用。
4. **文献名称**：*Targeting CIP2A with a recombinant antibody fragment inhibits lung cancer growth in vivo*
**作者**：Chen, Y., et al.
**摘要**：开发靶向重组CIP2A蛋白的单克隆抗体片段，在肺癌模型中验证了其抑制肿瘤生长的效果，为基于CIP2A的疗法奠定基础。
---
**注意**：以上文献为示例性质，实际引用需通过PubMed、Web of Science等数据库核实具体标题、作者及摘要。MPHOSPH9常被称为CIP2A(Cancerous Inhibitor of PP2A)，若检索结果有限，建议扩展关键词至“CIP2A”或“PP2A inhibitor”相关研究。
MPHOSPH9 (M-phase phosphoprotein 9), also known as BRRN1 or CDC5L, is a component of the chromosomal passenger complex (CPC), a key regulator of mitotic progression. This protein is highly conserved and plays a critical role in ensuring accurate chromosome segregation during cell division. It localizes to kinetochores during early mitosis and relocates to the spindle midzone during anaphase, coordinating multiple processes such as chromosome alignment, microtubule-kinetochore attachment correction, and cytokinesis.
MPHOSPH9 interacts with other CPC members, including Aurora B kinase, Survivin, and INCENP, to phosphorylate downstream targets that regulate sister chromatid cohesion, spindle assembly, and the spindle assembly checkpoint. Dysregulation of MPHOSPH9 has been linked to mitotic errors, genomic instability, and cancer progression. Overexpression is observed in various malignancies, correlating with poor prognosis and therapeutic resistance.
As a recombinant protein, MPHOSPH9 is utilized in studies exploring mitotic mechanisms, drug screening for antimitotic agents, and dissecting its structural-functional relationships. Its role in cancer biology makes it a potential biomarker or therapeutic target, particularly in tumors with chromosomal instability. Research continues to uncover its interactions with cell cycle checkpoints and DNA damage response pathways.
×
